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Background/aim: Treatment failure in hospitalized patients with community-acquired pneumonia is a major cause of mortality. The
aim of this study was to evaluate the factors affecting treatment success in community-acquired pneumonia.
Materials and methods: A total of 537 patients (mean age: 66.1 ± 15.8 years, 365 males) registered to the Turkish Thoracic Society
Pneumonia Database were analyzed. Of these, clinical improvement or cure, defined as treatment success, was achieved in 477, whereas
60 patients had treatment failure and/or died.
Results: Lower numbers of neutrophils (5989.9 ± 6237.3 vs. 8495.6 ± 7279.5/mm3), higher blood urea levels (66.1 ± 42.1 vs. 51.2 ±
38.2 mg/dL), higher Pneumonia Severity Index (PSI) scores (123.3 ± 42.6 vs. 96.3 ± 32.9), higher CURB-65 scores (2.7 ± 1.2 vs. 2.2 ±
0.9), lower PaO2/FiO2 ratios (216.3 ± 86.8 vs. 269.9 ± 65.6), and the presence of multilobar (33.3% vs. 16.4%) and bilateral (41.7% vs.
18.9%) radiologic infiltrates were related to treatment failure. The PSI score and PaO2/FiO2 ratio were independent parameters affecting
treatment results in multivariate linear regression analysis (P < 0.001).
Conclusion: The risk of treatment failure is high in patients with severe pneumonia and with respiratory failure. Effective treatment and
close monitoring are required for these cases.
Key words: Community-acquired pneumonia, treatment failure, pneumonia severity index, PaO2/FiO2

1. Introduction
Community-acquired pneumonia (CAP) remains a
leading cause of morbidity and mortality, particularly
in patients admitted to hospitals for severe disease.
Although most hospitalized patients with CAP
respond satisfactorily to treatment, some develop
treatment failure (TF) and may experience rapidly
progressive life-threatening pneumonia. The incidence
of TF in CAP is 10% to 15%, and it is associated with
significant increases in mortality and in cost (1).
Factors associated with TF are related to the initial
severity of the infection, the presence of comorbidities,
the causative organism, and the antibiotic therapy
administered (2).
Severity scores such as the Pneumonia Severity
Index (PSI) and CURB-65 have been validated and
their use has been recommended by international (3)
and national (4) guidelines for identifying patients
with a higher risk of poor prognosis. The PSI is a
* Correspondence: canangunduz@yahoo.com

prediction rule for prognosis that objectively stratifies
patients into quintiles of risk for short-term mortality
on the basis of 20 demographic and clinical variables
routinely available at presentation (4,5) (Table 1). The
British Thoracic Society’s CURB-65 score consists of 5
variables: new onset of confusion, blood urea nitrogen
of >7 mmol/L, respiratory rate ≥30 breaths/min, blood
pressure <90 mmHg systolic or <60 mmHg diastolic,
and age ≥65 years (4,6). Each risk factor scores one
point and the total score defines the risk level of the
patient, as well as predicting mortality and offering
a treatment approach (Table 2). However, there have
been no large-scale, multicenter studies in Turkey
regarding the prognostic use of these severity scoring
systems and other clinical or laboratory parameters.
The aim of this study was to evaluate the factors
affecting treatment success in hospitalized CAP
patients using the multicenter Turkish Thoracic
Society Pneumonia Database (TURCAP).
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Table 1. Pneumonia Severity Index.
Age

Laboratory findings

Male

Age (years)

BUN ≥ 30 mg/dL

20

Female

Age (years) – 10

Na < 130 mmol/L

20

Nursing home resident

10

Glucose ≥ 250 mg/dL

10

Hematocrit < 30%

10

Coexisting illnesses
Neoplastic disease

10

Radiographic findings

Liver disease

30

Pleural effusion

Congestive heart failure

20

Oxygenation

Cerebrovascular disease

10

Arterial pH < 7.35

30

Kidney disease

10

PaO2 < 60 mmHg

10

SaO2 < 90%

10

Physical examination findings
Altered mental status

20

Respiratory rate ≥ 30/min

20

Systolic BP < 90 mmHg

20

Temperature < 35 °C / ≥ 0 °C

15

Pulse ≥ 125/min

10

10

BP: Blood pressure; BUN: blood urea nitrogen; Na: sodium; PaO2: partial pressure of arterial oxygen;
SaO2: oxygen saturation.
Point assignments correspond with the following risk classes: age < 50 and no neoplastic,
cerebrovascular, liver or kidney disease class I; ≤70 class II; 71–90 class III; 91–130 class IV; >130
class V.
Table 2. CURB-65 severity score for CAP.
1. Confusion
2. Urea > 42.8 mg/dL (or blood urea nitrogen > 20 mg/dL [7 mmol/L])
3. Respiratory rate ≥ 30/min
4. Blood pressure (systolic < 90 mmHg or diastolic ≤ 60 mmHg)
5. Age ≥ 65
The existence of each criterion corresponds to 1 point.

2. Material and methods
A retrospective study was performed in patients with
CAP registered to TURCAP by four university hospitals
from September 2009 to September 2013. Briefly, this is
a web-based database, where several tertiary care centers
register relevant clinical data of their patients diagnosed
with CAP. The project was supported with a grant from
the Turkish Thoracic Society. Nonimmunocompromised
patients older than 18 years with the presence of a new
radiographic infiltrate and at least two compatible clinical
symptoms were included in the study. Patients with
missing data were excluded. The study was approved by
the local ethics committee.
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In order to determine the predictors of treatment
failure in this study population, we compared the findings
of the patients in whom the initial antibiotic succeeded
and failed. TF was defined as persistence or reappearance
of fever (37.8 °C or higher) or radiographic progression
(50% or more increase in the extent of infiltrates) including
pleural effusion and/or empyema, or worsening of the
clinical condition, which would necessitate change in
antibiotic treatment or death. No distinction was made for
early and late failure. Treatment success (TS) was defined
as improvement or resolution of all symptoms and clinical
and radiographic signs of pneumonia by days 10–15,
without the appearance of new signs and/or symptoms
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and without any need to change the antibiotic therapy.
The demographic data (age, sex, smoking history,
comorbidities), admission to hospital or history of
antibiotherapy in the preceding 3 months, laboratory
findings including C-reactive protein, procalcitonin,
culture results, and radiologic findings of the two groups
were compared. Initial risk class was recorded according to
CURB-65 and PSI scores.
2.1. Statistical analysis
SPSS was used for statistical analysis (SPSS Inc., Chicago,
IL, USA). The t-test and chi-square test were used to
conduct between-group analyses. Linear multivariate
regression analysis was used for examining independent
variables.
3. Results
Four tertiary care centers contributed data to this study.
Out of 788 patients who were registered from these four
centers, 251 patients were excluded because of missing
data. Thus, 537 patients (mean age: 66.1 ± 15.8 years, 365
males) were included in the analysis. Of these, 477 (89%)
patients had TS, whereas TF was documented in 60 (11%)

patients. There were no significant differences between the
two patient groups in demographic data including age, sex,
smoking history, comorbidities, history of hospitalization,
or antibiotherapy in the preceding 3 months (Table 3).
Patients in whom the initial antibiotic regimen failed had
lower numbers of neutrophils (5989.9 ± 6237.3 vs. 8495.6
± 7279.5/mm3; P = 0.019), higher blood urea levels (66.1 ±
42.1 vs. 51.2 ± 38.2 mg/dL; P = 0.006), higher procalcitonin
levels (6.3 ± 17.4 vs. 26.6 ± 70.1 ng/mL; P = 0.027), higher
PSI scores (123.3 ± 42.6 vs. 96.3 ± 32.9, P < 0.001) and
CURB-65 scores (2.7 ± 1.2 vs. 2.2 ± 0.9, P < 0.001), and
lower PaO2/FiO2 ratios (216.3 ± 86.8 vs. 269.9 ± 65.6, P
= 0.010). They were also found to have more frequent
multilobar (33.3% vs. 16.4%, P = 0.002) and bilateral
(41.7% vs. 18.9%, P < 0.001) radiographic infiltrates (Table
4).
There was no difference between the two groups
regarding the percentage of patients who received
guideline-concordant antibiotherapy (75% vs. 68.3%,
P = 0.182). A causative pathogen was identified and
susceptibility tests were performed in only 67 patients
(12.5%). There were too few patients to perform statistical
analysis (Table 5). However, patients with more severe

Table 3. Demographic data of treatment success and failure groups.
Age (years)

65.6 ± 15.7

69.7 ± 15.8

NS

Sex, male (%)

322 (67.5)

43 (71.6)

NS

Smoking history, pack-years

40.0 ± 277

36.3 ± 15.8

NS

Comorbidity, n (%)

409 (85.7)

55 (91.7)

NS

Hospitalization in the preceding 3 months, n (%)

78 (16.4)

16 (26.7)

NS

Antibiotic use in the preceding 3 months, n (%)

100 (21.0)

15 (25.0)

NS

Table 4. Comparison of clinical and laboratory findings in treatment success and failure groups.
White blood cell count (cells/mm3)

12,148.9 ± 8133.2

11,111.5 ± 6769.9

NS

Neutrophil count (cells/mm3)

8495.6 ± 7279.5

5989.9 ± 6237.3

0.019

Urea (mg/dL)

51.2 ± 38.2

66.1 ± 42.1

0.006

Albumin (g/L)

3.4 ± 2.3

3.07 ± 0.57

NS

C - reactive protein (mg/dL)

15.6 ± 10.8

17.1 ± 11.3

NS

Procalcitonin (ng/mL)

6.3 ± 17.4

26.6 ± 70.1

0.027

PaO2/FiO2

269.9 ± 65.6

216.3 ± 86.8

0.01

CURB-65 score

2.2 ± 0.9

2.7 ± 1.2

<0.001

PSI score

96.3 ± 32.9

123.3 ± 42.6

<0.001

Culture (+) respiratory sample, n (%)

61 (12.8)

6 (10)

NS
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Table 5. The effect of appropriate antibiotherapy on treatment outcome in patients
in whom a microorganism was isolated.
Treatment success

41 (67.2%)

20 (32.8%)

61

Treatment failure

5 (83.3%)

1 (16.7%)

6

Total

46

21

67

CAP, i.e. with PSI scores higher than 90, appeared to be
more frequently infected with drug-resistant bacteria
(enteric gram-negative bacilli, bacteria that produced
extended-spectrum beta-lactamases, Pseudomonas, and
Acinetobacter) (Table 6).
Multivariate linear regression analysis showed that
PSI score (P < 0.001) and PaO2/FiO2 ratio (P < 0.001)
were the only independent parameters affecting treatment
results (Table 7). Thus, inpatients with an admission PaO2/
FiO2 ratio below 200 or a PSI score greater than 90 had
significantly higher risks for treatment failure (RR: 5.2 and
3.1, respectively) (Table 8). Treatment failure rates tended
to be higher in the PSI > 90 group compared to the PSI
≤ 90 group (47 vs. 11, respectively; P < 0.001). Mortality
rate was also significantly higher in the group with PSI >
90 compared to the PSI ≤ 90 group (24 vs. 2, respectively;
P < 0.001).
4. Discussion
This study showed that a high PSI score and a low PaO2/
FiO2 ratio were the only independent parameters that were
associated with TF. The magnitude of respiratory failure
and the severity of the disease were significantly predictive
particularly for PaO2/FiO2 < 200 and PSI > 90. In our

study, where we aimed to define the risk factors affecting
treatment response in a large population, our findings
were substantially consistent with previous reports.
Since CAP is related to high mortality and morbidity,
defining the predicting factors for treatment outcome is
important and would help clinicians to better assess and
manage their patients. Several studies have been performed
with heterogeneous results. In a multicenter observational
prospective study performed in 15 Spanish hospitals, TF
was observed in 15.1% of the patients (1), a rate similar
to our study. The factors associated with treatment failure
were found to be the presence of high-risk pneumonia,
liver disease, multilobar infiltrates, Legionella pneumonia,
gram-negative pneumonia, pleural effusion, cavitation,
leukopenia, and discordant antimicrobial therapy.
Arancibia et al. examined the causes of antimicrobial
treatment failure in CAP patients who were admitted
to the hospital and had extensive microbiological
investigations (7). TF was mostly due to antimicrobial
resistance of the primary pathogen and acquisition of a
nosocomial infection. In another Spanish study performed
by Rosón et al. (8), independent factors associated with
early failure were high-risk pneumonia (PSI score greater
than 90), multilobar infiltrates, Legionella pneumonia,

Table 6. Causative bacteria in patients with less severe (PSI ≤ 90) and more
severe (PSI > 90) pneumonia.
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S. pneumococcus

4

7

11

H. influenzae

2

3

5

M. catarrhalis

2

0

2

Methicillin-sensitive S. Aureus

0

4

4

Enteric gram-negative bacilli

0

3

3

ESBL-producing K. Pneumoniae

1

4

5

ESBL-producing E. coli

1

8

9

P. aeruginosa

7

8

15

A. baumannii

3

1

4

Other

2

3

5

Total

22

41

63
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Table 7. Factors associated with treatment success in a
multivariate model.
PaO2/FiO2

0.548

5.587

<0.001

PSI score

0.435

2.983

0.004

CURB-65 score

0.029

0.221

0.826

Procalcitonin

–0.022

–0.533

0.595

Urea

–0.058

–0.749

0.457

Neutrophils

0.026

0.395

0.694

gram-negative pneumonia, and discordant antimicrobial
therapy. In the CAPITAL study (9), younger age, treatment
with levofloxacin, and the absence of COPD and asthma
were identified as significant predictors of symptom
resolution in CAP. Finally, in a study on patients with
severe CAP, age, CURB-65 score, presence of septic shock,
acute respiratory distress syndrome, and acute renal failure
during the first 24 h of ICU admission were found to be
independent predictors of mortality (10).
In accordance with these studies, the findings in our
study also highlight the importance of the severity of
pneumonia, as indicated by high PSI scores and low PaO2/
FiO2 ratios. Besides, TF was also more frequently observed
in patients with lower leukocyte counts and multilobar
involvement.
It has been proposed that biological markers, including
CRP and procalcitonin, may be useful in identifying
patients with a higher risk of deterioration (11–14). This
study showed that there was no difference in CRP levels
at admission between TF and TS groups. On the other
hand, patients who failed treatment were found to have
higher initial procalcitonin levels, although this was not an
independent predictor of treatment outcome. The study by
Kruger et al. (15) also found that admission procalcitonin
levels predicted the outcome of CAP as well as the CRB-65
score and with better accuracy than the CRP levels.
This study has several limitations. First, it was
retrospective in nature, and a third of the patient
population had to be excluded because of missing data;
however, these patients were similar to those included in
the study and there was no indication that the results would
differ if all of the patient population was included. Second,

no distinction could be made between early and late
treatment failures. All participating centers were required
to register their patients’ data at admission and on days 3–7
of antibiotic treatment. Thus, the presented data reflect the
clinical picture of this time interval. Third, and perhaps
most importantly, we were not able to examine the effect of
the causative pathogens and their resistance to antibiotics
on the treatment outcome, as a pathogen was identified
in only 12.5% of the study population. In a recent large
multicenter prospective cohort study in the United States
evaluating 2259 CAP patients with respiratory specimens,
a pathogen was detected in 853 cases (38%) and the
most common pathogens were human rhinovirus (in 9%
of patients), influenza virus (in 6%), and Streptococcus
pneumoniae (in 5%) (16). Viral pathogens could not be
evaluated in our study since serological tests were not
routinely performed in our retrospective study. The low
rate of pathogen identification in our study possibly stems
from the fact that most of the patients admitted to tertiary
care centers are already treated with antimicrobials.
Besides, the patients present mostly to the emergency
room first, where insufficient efforts are made to obtain
respiratory samples for microbiologic examinations.
As there were too few patients in whom a pathogen was
identified, no statistical analysis could be performed to
determine whether the appropriateness of the antibiotic
regimen affects treatment outcome. However, drugresistant bacteria were more frequently isolated in patients
with more severe pneumonia and further studies that
include larger patient populations (and higher rates of
pathogen isolation) may shed light on the effect of drug
resistance and appropriateness of antibiotic regimens.
No association was found between TF and
antimicrobial use that is discordant with the national
guidelines. When the data were examined in detail, it
was observed that discordant treatment mostly consisted
of larger-spectrum regimens, possibly chosen because of
failure of prior therapy. These regimens resulted in similar
rates of treatment success, but were probably associated
with higher costs and unfavorable effects on antimicrobial
resistance.
This study showed once again that the PSI is a reliable
predictor of clinical outcome in CAP and is a better tool in
this respect than CURB-65. Thus, patients in PSI groups
IV and V (with scores higher than 90) were found to have

Table 8. Predicted risk ratios for PaO2/FiO2 and PSI.
PaO2/FiO2
PSI score

<200

27.2

5.2 (1.97–13.6)

<0.001

<300

11.9

2.6 (0.73–9.1)

NS

>90

13.1

3.1 (1.58–6.19)

<0.001
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a 3.13-fold increased risk for treatment failure. A variety
of other studies have suggested that the PSI and CURB65 provide similar information, though the PSI is more
weighted toward age and comorbidity and CURB-65 is
more weighted toward acute physiological dysfunction
(17). We were not able to assess the predictive value of the
SMART-COP score as albumin levels were not regularly
registered in the database. This latter tool has been shown
to better identify CAP patients who require intensive
respiratory and vasopressor support (18) and who are at
higher risk of treatment failure. In the same line, we have

shown that the second independent variable associated
with treatment failure was the oxygenation level, as
measured with the PaO2/FiO2 ratio. Thus, risk assessment
tools like SMART-COP, which put more weight on the
oxygenation level of the patient, may be more sensitive in
identifying at-risk patients.
In conclusion, our findings show that the risk of
treatment failure is high in CAP patients with high PSI
scores (>90) and with respiratory failure (PaO2/FiO2
< 200). Effective treatment and close monitoring are
required for these cases.
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